Pfizer appeals European patent office decision on Xalatan
This article was originally published in Scrip
Executive Summary
Pfizer says it has lodged an appeal with the European Patent Office after its opposition division revoked a patent that covers latanoprost, the basis of the US firm's Xalatan prostaglandin eye product.